Product News

Share this content:

FDA OK'd a new indication for Eli Lilly's Symbyax, a Zyprexa and Prozac combination therapy. Symbyax is now indicated for patients with treatment-resistant depression, in addition to its prior indication for bipolar depression.

Share this content:
Scroll down to see the next article